Dextromethorphan and guaifenesin use ought to be monitored diligently in sufferers with "poor metabolizer" CYP2D6 enzyme degrees and individuals who're sedated. This combination medication provides a massive median toxic dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these patients. et al. The affect of CYP2D6 polymorphism https://k2-paper-for-sale-usa10875.bluxeblog.com/62253176/a-review-of-dextromethorphan-dxm-for-sale-in-usa